Showing results (271-280 of 679) with videos related to

Sort By:
Pageof 68
Blood Cancer Journal|August 1, 2023
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panelNoopur Raje, Kenneth Anderson, Hermann Einsele, et al.
Mycoses|April 22, 2017
Prevalence of the reversed halo sign in neutropenic patients compared with non-neutropenic patients: Data from a single-centre study involving 27 patients with pulmonary mucormycosis (2003-2016)Jessie Bourcier, Pierre-Marie Heudes, Florent Morio, et al.
Blood|August 21, 2010
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation studyPhilippe Moreau, Arnaud Jaccard, Lotfi Benboubker, et al.
BMC Cancer|August 30, 2019
The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myelomaLina Benaniba, Benoit Tessoulin, Sabrina Trudel, et al.
Cancers|May 21, 2020
Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1Adrien Bosseboeuf, Nicolas Mennesson, Sophie Allain-Maillet, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2014
Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adultsPierre Peterlin, Jacques Delaunay, Thierry Guillaume, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|April 2, 2013
HLA-G 3' UTR-2 haplotype is associated with Human African trypanosomiasis susceptibilityDavid Courtin, Jacqueline Milet, Audrey Sabbagh, et al.
Cancer|October 7, 2014
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trialMohamad Mohty, Florent Malard, Didier Blaise, et al.
Blood|February 24, 2016
Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survivalFlorent Malard, Myriam Labopin, Patrice Chevallier, et al.
Leukemia|April 25, 2020
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myelomaHartmut Goldschmidt, Meletios A Dimopoulos, S Vincent Rajkumar, et al.
Pageof 68